Active — Not RecruitingNot Applicable

Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

China1,076 participantsStarted 2019-12-01

Plain-language summary

Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C. For the treatment of PVTT, there are differences between Eastern and Western guidelines, with systemic drugs being the standard of care in Western countries, while surgical treatment is often actively practiced in the Asia-Pacific region. More research is needed to explore the differences between these two approaches.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 18-75 years * Pathological type is HCC, and with PVTT * No extrahepatic HCC * Eastern Cooperative Oncology Group (ECOG) performing status of 0-1 and Child-Pugh grade A for the liver resection group * ECOG performing status of 0-2 and Child-Pugh grade A-B for the locoregional-based group * Adequate hematologic and organ function Exclusion Criteria: * Any history of other malignant tumors or recurrent HCC * Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency * Any persistent serious liver resection or locoregional therapy-related complications * Esophageal and/or gastric variceal bleeding within 6 months * Inability or refusal to comply with the treatment and monitoring * Participation in other clinical trials

What they're measuring

Overall survival

Timeframe: From date of include in this research until the date of death from any cause, whichever came first, assessed up to 60 months.

Trial details

NCT IDNCT06248528

SponsorChen Xiaoping

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31